BEIJING, China, November 5, 2026 — Cygnus Biosciences (Beijing) Co., Ltd. (“Cygnus Biosciences”) and Beijing SeekGene BioSciences Co., Ltd (“SeekGene”) have announced a strategic collaboration to advance single-cell research by bringing together SeekGene’s expertise in single-cell analysis and Cygnus’s sequencing technologies to support major research initiatives, co-develop integrated solutions and expand into international markets.

SeekGene CEO Zongwen Li (left) and Cygnus Biosciences CEO Zitian Chen (right)

SeekGene’s portfolio includes the SeekGene's SeekOne™ DD single-cell and SeekSpace™ spatial multi-omics platforms, with capabilities spanning sample processing, library preparation and data analysis. At Cygnus, the sequencing platforms are built on core technologies including LumoSeq sequencing chemistry, Error-correction Coding (ECC) and LoopCell technology. The collaboration will bring these complementary capabilities closer together, strengthening compatibility between experimental workflows and sequencing platforms.

“SeekGene has always focused on advancing single-cell and spatial multi-omics technologies. This collaboration connects our work in sample processing and multi-omics with Cygnus’s sequencing chemistry and instrument platforms, creating a more integrated, independently developed workflow for researchers,” said Zongwen Li, Founder and CEO of SeekGene.

“The value of life science tools lies in their ability to support frontier research and address real scientific needs. At Cygnus, we are committed to innovation in core sequencing technologies. This collaboration brings sequencing innovation closer to single-cell applications and gives researchers more options,” said Zitian Chen, Co-founder and CEO of Cygnus Biosciences.

Major research initiatives will drive the development of integrated capabilities across single-cell transcriptomics, spatial transcriptomics and multi-omics testing. Joint innovation centers and shared laboratories will provide a lasting framework for collaboration with research institutions and strengthen long-term research capacity.

Internationally, the partnership will pair broader market access with deeper engagement across research communities. Academic exchange, informed by validation data and application findings cleared for public release, will help connect the companies’ solutions with global research priorities.

Looking ahead, the partnership will extend into emerging fields such as AI virtual cells. Cygnus and SeekGene will examine how high-quality, standardized single-cell data, integrated with spatial and multi-omics information, can open new avenues for research and contribute to a more open, collaborative ecosystem for single-cell science.

About SeekGene

Founded in 2018, SeekGene is a technology-driven platform company dedicated to advancing single-cell sequencing technologies. Guided by the vision of technology-powered innovation, SeekGene focuses on decoding multidimensional biological information from individual cells — "All in One Cell". Built around the SeekOne™ DD microfluidic system, SeekGene has established a platform that supports multiple single-cell assay workflows across transcriptomics, epigenomics, and spatial omics — "All in SeekOne™ DD". SeekGene technologies are used by over 1,000 research organizations worldwide and have contributed to studies published in Cell, Science, and Nature.

About Cygnus Biosciences

Cygnus Biosciences is a global innovator in sequencing technologies, dedicated to developing advanced sequencing platforms and proprietary core technologies for Sequencing the Future. With scalable sequencing solutions ranging from Gb to Tb, Cygnus serves applications across life science research, clinical diagnostics, pharmaceutical R&D, agriculture genomics, public health, and precision medicine. Cygnus has established an integrated sequencing ecosystem spanning instruments, consumables, and automated bioinformatics tools, with independent development and manufacturing of core technologies. Its platforms support research, clinical testing, population genomics, and biobank projects, with key technological advances published in leading scientific journals including Nature Biotechnology, Nature Biomedical Engineering, and National Science Review.